Literature DB >> 18359151

Antitumor effects of somatostatin.

Stéphane Pyronnet1, Corinne Bousquet, Souad Najib, Rania Azar, Hanane Laklai, Christiane Susini.   

Abstract

Since its discovery three decades ago as an inhibitor of GH release from the pituitary gland, somatostatin has attracted much attention because of its functional role in the regulation of a wide variety of physiological functions in the brain, pituitary, pancreas, gastrointestinal tract, adrenals, thyroid, kidney and immune system. In addition to its negative role in the control of endocrine and exocrine secretions, somatostatin and analogs also exert inhibitory effects on the proliferation and survival of normal and tumor cells. Over the past 15 years, studies have begun to reveal some of the molecular mechanisms underlying the antitumor activity of somatostatin. This review covers the present knowledge in the antitumor effect of somatostatin and analogs and discusses the perspectives of novel clinical strategies based on somatostatin receptor sst2 gene transfer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359151     DOI: 10.1016/j.mce.2008.02.002

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  67 in total

1.  Negative regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5.

Authors:  Guisheng Zhou; Shi-He Liu; Kelly M Shahi; Hua Wang; Xueyan Duan; Xia Lin; Xin-Hua Feng; Min Li; William E Fisher; Francesco J Demayo; David Dawson; F Charles Brunicardi
Journal:  Mol Endocrinol       Date:  2012-06-05

2.  ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.

Authors:  Hua Li; Benjamin G Bitler; Vinod Vathipadiekal; Marie E Maradeo; Michael Slifker; Caretha L Creasy; Peter J Tummino; Paul Cairns; Michael J Birrer; Rugang Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-05

Review 3.  Extrapituitary growth hormone.

Authors:  S Harvey
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

4.  Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Authors:  Renzo Cescato; Kimberly A Loesch; Beatrice Waser; Helmut R Mäcke; Jean E Rivier; Jean Claude Reubi; Agnes Schonbrunn
Journal:  Mol Endocrinol       Date:  2009-11-12

Review 5.  Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.

Authors:  Bassam Abu-Wasel; Caolan Walsh; Valerie Keough; Michele Molinari
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

Review 6.  Rare cystic liver lesions: a diagnostic and managing challenge.

Authors:  Andreas Bakoyiannis; Spiros Delis; Charina Triantopoulou; Christos Dervenis
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 7.  The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.

Authors:  Mauro Cives; Jonathan Strosberg
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

8.  Synthesis, in vitro biological activity, hydrolytic stability and docking of new analogs of BIM-23052 containing halogenated amino acids.

Authors:  Dancho Danalev; Desislava Borisova; Spaska Yaneva; Maya Georgieva; Anelia Balacheva; Tatyana Dzimbova; Ivan Iliev; Tamara Pajpanova; Zdravka Zaharieva; Ivan Givechev; Emilia Naydenova
Journal:  Amino Acids       Date:  2020-11-19       Impact factor: 3.520

9.  Gene expression profiles of colonic mucosa in healthy young adult and senior dogs.

Authors:  Dong Yong Kil; Brittany M Vester Boler; Carolyn J Apanavicius; Lawrence B Schook; Kelly S Swanson
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

Review 10.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

Authors:  Marialuisa Appetecchia; Roberto Baldelli
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.